BioLineRx (BLRX) Reports In-Line Q1 EPS

BioLineRx (NASDAQ: BLRX) reported Q1 EPS of ($0.06), in-line with the analyst estimate of ($0.06). Revenue for the quarter came in at $0 versus the consensus estimate of $10 thousand.

For earnings history and earnings-related data on BioLineRx (BLRX) click here.

You May Also Be Interested In

• Kroger (KR) Reports In-Line Q1 EPS, Beats on Revenue; Offers FY27 EPS Guidance
• Pfizer reaffirms 2026 guidance after CFO transition news
• Hyperscale Data launches $300M at-the-market stock offering